A number of states are moving reform bills concerning the study or straight out legalizing the use of psychedelic substances for therapeutic purposes. Others have already passed legislation and its implementation is underway. A short recap of the latest moves as of Sept. 7:

Changes affect provisions on substance transfer and therapeutic use, delay the decriminalization of communal use, and reduce personal possession amounts “until a framework for the therapeutic use, which would include community-based healing, facilitated and supported use, risk reduction, and other related services, of the specified controlled substances is developed and adopted.”

New allowed personal amounts: 1 gr. or up to one ounce of a plant or fungi containing either psilocybin or psilocin; 1 gr. of DMT; and 4 gr. of mescaline. Adults over 21 could possess an “amount of spores or mycelium capable of producing an allowable amount of a plant or fungi which contain a controlled substance” legalized under the bill. 

Additionally, the revised bill calls on the California Health and Human Services Agency (CHHSA) to create a workgroup to study and recommend to the legislature the establishment of a regulatory framework for the facilitated therapeutic use of psychedelics by Jan. 2025.

Meanwhile, AB 1021 legalizing Schedule I controlled substances for “legitimate medical purposes” was ordered a third reading in the Senate after which it …

Full story available on Benzinga.com

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.